title: The Dogged Search for Cryptic Effects of Ticagrelor: Wishful Thinking or Real Benefits Beyond P2Y12 Inhibition?
authors: From Inova Center for Thrombosis Research and Drug Development, Inova Heart and Vascular Institute, Falls Church, VA (P.A.G., U.S.T.); and Cardiovascular Center, Changwon Gyeongsang National University Hospital, Gyeongsangnam-do, Republic of Korea (Y.-H.J.). Paul.Gurbel@inova.org.
authors: Paul A
authors: PA
authors: Gurbel
authors: From Inova Center for Thrombosis Research and Drug Development, Inova Heart and Vascular Institute, Falls Church, VA (P.A.G., U.S.T.); and Cardiovascular Center, Changwon Gyeongsang National University Hospital, Gyeongsangnam-do, Republic of Korea (Y.-H.J.).
authors: Young-Hoon
authors: YH
authors: Jeong
authors: From Inova Center for Thrombosis Research and Drug Development, Inova Heart and Vascular Institute, Falls Church, VA (P.A.G., U.S.T.); and Cardiovascular Center, Changwon Gyeongsang National University Hospital, Gyeongsangnam-do, Republic of Korea (Y.-H.J.).
authors: Udaya S
authors: US
authors: Tantry
mesh_terms: D000241:Adenosine / Q000031:analogs & derivatives; D010975:Platelet Aggregation Inhibitors; D058921:Purinergic P2Y Receptor Antagonists; D058925:Receptors, Purinergic P2Y12; D000077486:Ticagrelor; D013988:Ticlopidine
chemical_list: D010975:Platelet Aggregation Inhibitors; D058921:Purinergic P2Y Receptor Antagonists; D058925:Receptors, Purinergic P2Y12; D000077486:Ticagrelor; D000241:Adenosine; D013988:Ticlopidine
keywords: Editorials; clopidogrel; platelet aggregation inhibitor; purinergic P2Y receptor antagonists; reperfusion injury